Key Takeaway: Savara Inc. announced its participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference, scheduled for May 19th at NASDAQ headquarters in New York. The management team will engage in a fireside chat, which will be available for live streaming and later replay. Savara focuses on rare respiratory diseases, with its lead program, MOLBREEVI, in Phase 3 development.
Price reaction · baseline $5.12 (2026-05-11 close) · hit pre-market · clean, no other SVRA news in the window
day 0 close · peak
-0.8%
Market Sentiment Analysis
POSITIVE FACTORS
Savara is actively participating in a notable investor conference.
The company is focused on addressing rare respiratory diseases.
MOLBREEVI is in Phase 3 development, indicating progress in their pipeline.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc.(Nasdaq:SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will participate in a fireside chat at the H.C. Wainwright & Co. 4thAnnual BioConnect Investor Conference on Tuesday, May 19that 10:00am ET in New York, NY at the NASDAQ headquarters.
The live webcast and subsequent replay will be available on the“Events & Presentations”section of the Company’s corporate website and will be archived for 90 days.
About Savara
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is delivered via a proprietary investigational eFlow®Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of MOLBREEVI. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found atwww.savarapharma.comandLinkedIn.
*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication. MOLBREEVI is a trademark of Savara Inc.
Frequently Asked Questions
When is Savara participating in the BioConnect Conference?
Savara will participate in the BioConnect Conference on May 19th at 10:00 am ET.
Where is the BioConnect Conference being held?
The conference will be held at the NASDAQ headquarters in New York, NY.
What is Savara's lead program?
Savara's lead program is MOLBREEVI, aimed at treating autoimmune pulmonary alveolar proteinosis.
How can I watch the conference?
The conference will be available via live webcast and archived for 90 days on Savara's website.